NEW SECURITY WARNINGS FOR TOFACITINIB:
ANALYSIS OF PATIENTS IN RISK

M.J. LOPEZ-MUÑOZ1, A. ALCALA-SOTO1, M. VÁZQUEZ-REAL1, M.D.V. SANCHEZ MATAMOROS PIZZAZA1, D. RUIZ-PÉREZ1, J.F. SIERRA-SÁNCHEZ1. 1HOSPITAL UNIVERSITARIO JEREZ DE LA FRONTERA, PHARMACY SERVICE, JEREZ DE LA FRONTERA-CÁDIZ, SPAIN.

Objetives

The objective of this study is to detect patients under treatment with tofacitinib at an increased risk of major adverse cardiovascular events and malignances in order to communicate it to healthcare professionals.

Materials and Methods

Retrospective study of patients under treatment with tofacitinib from January to September 2021. The following factors were considered as risk factors: 65 years or more, cardiovascular risk factors, and current malignances. We did a personalized report that included a summary of the drug safety warning and patients under treatment considered to be in risk to each healthcare professional, offering them other treatment options based on efficacy, safety and cost.

Results

We reviewed 36 patients under treatment with tofacitinib, 28 female (73%), 51.6 average age. We sent 11 personalized reports to healthcare professionals

Conclusions

One of three patients in treatment with tofacitinib were affected by the security alert: considered as risk population for major adverse cardiovascular events and malignances. This study allowed finding patients in risk and communicate it to healthcare professionals, providing them another treatment option based on efficacy, safety and cost.